GCP
SYRS

GSA Capital Partners’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

GSA Capital Partners’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,905
Closed -$34K – 2106
2024
Q3 		$34K Buy
+15,905
New +$57.1K ﹤0.01% 1527
2023
Q3 		– Sell
-27,460
Closed -$86K – 2000
2023
Q2 		$86K Buy
27,460
+10,613
+63% +$34.1K 0.01% 1390
2023
Q1 		$45K Buy
+16,847
New +$65.3K ﹤0.01% 1406
2022
Q2 		– Sell
-37,221
Closed -$443K – 1881
2022
Q1 		$443K Buy
37,221
+13,008
+54% +$233K 0.06% 625
2021
Q4 		$789K Buy
24,213
+13,179
+119% +$534K 0.1% 322
2021
Q3 		$493K Sell
11,034
-3,065
-22% -$150K 0.05% 703
2021
Q2 		$768K Buy
14,099
+7,616
+117% +$451K 0.09% 367
2021
Q1 		$485K Buy
+6,483
New +$674K 0.08% 371
2020
Q1 		– Sell
-2,776
Closed -$192K – 1652
2019
Q4 		$192K Buy
+2,776
New +$168K 0.02% 1268
2019
Q3 		– Sell
-2,007
Closed -$186K – 1768
2019
Q2 		$186K Sell
2,007
-1,849
-48% -$129K 0.02% 1258
2019
Q1 		$352K Sell
3,856
-1,402
-27% -$97.6K 0.04% 901
2018
Q4 		$293K Sell
5,258
-2,880
-35% -$219K 0.03% 852
2018
Q3 		$969K Buy
8,138
+4,220
+108% +$490K 0.05% 697
2018
Q2 		$400K Sell
3,918
-6,972
-64% -$863K 0.02% 1265
2018
Q1 		$1.41M Buy
+10,890
New +$1.19M 0.07% 454
2017
Q4 		– Sell
-1,630
Closed -$240K – 1864
2017
Q3 		$240K Buy
+1,630
New +$307K 0.02% 1360

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

GSA Capital Partners's SYRS Position: Q4 2024 in Review

GSA Capital Partners sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2024, closing a stake of 15,905 shares — an estimated $34K sold.

GSA Capital Partners first reported a position in SYRS in Q3 2017 and held it in 16 quarters. The position peaked at $1.41M in Q1 2018. 44 funds tracked by Wall St. Rank hold SYRS as of Q4 2024.

  • GSA Capital Partners reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • GSA Capital Partners sold 15,905 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $34K.
  • GSA Capital Partners first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 16 quarters.
  • GSA Capital Partners's Syros Pharmaceuticals, Inc. Common Stock position peaked at $1.41M in Q1 2018.
  • 44 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on GSA Capital Partners's 13F filing for Q4 2024, filed 7 Feb 2025.